Insider · CIK 0001627642
David Zaccardelli
ceopresidentofficerdirector
Files at VRNA (Verona Pharma plc), SABS (SAB Biotherapeutics, Inc.). First filing Oct 22, 2024, latest Aug 5, 2025.
David Zaccardelli files SEC Form 4 as CEO, president and director at VRNA (Verona Pharma plc), and also at SABS (SAB Biotherapeutics, Inc.). Since Oct 22, 2024, David Zaccardelli has reported 0 open-market buys worth $0 and 12 open-market sells worth $26M, the latest filed on Aug 5, 2025.
A track record needs three past buys with six months of prices behind them; David Zaccardelli has 0, so none is measured yet.
The newest scored trade: sold $2.7M of VRNA on Aug 1, 2025, filed Aug 5, 2025, scored 30 (weak), under a 10b5-1 plan.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 12
$0 bought, $26M sold
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 30Weak | Verona Pharma plc | $2.7M 208,912 shares | -2% | - | |
| 45Moderate | Verona Pharma plc | $4.6M 400,000 shares | -3% | - | |
| 45Moderate | Verona Pharma plc | $3.7M 400,000 shares | -3% | - | |
| 30Weak | Verona Pharma plc | $5.3M 587,008 shares | -4% | - | |
| 27Weak | Verona Pharma plc | $811k 90,360 shares | -1% | - | |
| 45Moderate | Verona Pharma plc | $4.4M 870,672 shares | -6% | - | |
| 40Moderate | Verona Pharma plc | $627k 125,328 shares | -1% | - | |
| 20Weak | Verona Pharma plc | $8,000 1,600 shares | -0% | - | |
| 20Weak | Verona Pharma plc | $12k 2,400 shares | -0% | - | |
| 33Weak | Verona Pharma plc | $619k 141,032 shares | -1% | - | |
| 33Weak | Verona Pharma plc | $634k 144,816 shares | -1% | - | |
| 38Weak | Verona Pharma plc | $2.3M 514,152 shares | -3% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Jun 11, 2025 | VRNA Verona Pharma plc | 50,000 0.06% of outstanding | $4.3M | Jun 11, 2025 | $9.9M |
| May 27, 2025 | VRNA VERONA PHARMA PLC | 50,000 0.06% of outstanding | $3.8M | May 27, 2025 | $6.1M |
| May 2, 2025 | VRNA Verona Pharma plc | 50,000 0.06% of outstanding | $3.6M | May 2, 2025 | $811k |
| Nov 12, 2024 | VRNA VERONA PHARMA PLC | 125,000 0.02% of outstanding | $4.8M | Nov 11, 2024 | $7.0M |
| Oct 18, 2024 | VRNA Verona Pharma plc | 100,000 0.02% of outstanding | $3.5M | Oct 18, 2024 | $3.5M |
Transactions
The newest 50 of 51 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 5, 2026 | SABS SAB Biotherapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +240,000 | $0.00 | $0 | 240,000 | Jan 7, 2026 |
| Oct 7, 2025 | VRNA Verona Pharma plc | DDisposition to issuer Ordinary Shares | -12,176,144 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | VRNA Verona Pharma plc | MOption exercise Ordinary Shares | +3,285,280 | - | - | 3,285,280 | Oct 8, 2025 |
| Oct 7, 2025 | VRNA Verona Pharma plc | DDisposition to issuer Ordinary Shares | -3,285,280 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | VRNA Verona Pharma plc | MOption exercise Restricted Share Unitderivative | -800,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | VRNA Verona Pharma plc | MOption exercise Restricted Share Unitderivative | -389,792 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | VRNA Verona Pharma plc | MOption exercise Restricted Share Unitderivative | -445,536 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | VRNA Verona Pharma plc | AGrant or award Restricted Share Unitderivative | +1,649,952 | - | - | 1,649,952 | Oct 8, 2025 |
| Oct 7, 2025 | VRNA Verona Pharma plc | MOption exercise Restricted Share Unitderivative | -1,649,952 | - | - | 0 | Oct 8, 2025 |
| Aug 29, 2025 | VRNA Verona Pharma plc | GGift Ordinary Shares | -1,200,000 | $0.00 | $0 | 12,176,144 | Sep 3, 2025 |
| Aug 1, 2025 | VRNA Verona Pharma plc | MOption exercise Ordinary Shares10b5-1 | +255,696 | $0.00 | $0 | 13,585,056 | Aug 5, 2025 |
| Aug 1, 2025 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -208,912 | $13.14 | $2.7M | 13,376,144 | Aug 5, 2025 |
| Aug 1, 2025 | VRNA Verona Pharma plc | MOption exercise Restricted Stock Unitsderivative10b5-1 | -200,000 | $0.00 | $0 | 800,000 | Aug 5, 2025 |
| Aug 1, 2025 | VRNA Verona Pharma plc | MOption exercise Restricted Stock Unitsderivative10b5-1 | -55,696 | $0.00 | $0 | 389,792 | Aug 5, 2025 |
| Jul 7, 2025 | VRNA Verona Pharma plc | MOption exercise Ordinary Shares | +229,512 | $0.00 | $0 | 13,419,680 | Jul 9, 2025 |
| Jul 8, 2025 | VRNA Verona Pharma plc | FTax withholding Ordinary Shares | -90,320 | $11.44 | $1.0M | 13,329,360 | Jul 9, 2025 |
| Jul 7, 2025 | VRNA Verona Pharma plc | AGrant or award Restricted Share Unitsderivative | +675,048 | $0.00 | $0 | 675,048 | Jul 9, 2025 |
| Jul 7, 2025 | VRNA Verona Pharma plc | MOption exercise Restricted Share Unitsderivative | -229,512 | $0.00 | $0 | 445,536 | Jul 9, 2025 |
| Jun 11, 2025 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -400,000 | $11.40 | $4.6M | 13,190,168 | Jun 13, 2025 |
| May 27, 2025 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -33,600 | $9.53 | $320k | 13,956,568 | May 29, 2025 |
| May 28, 2025 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -157,704 | $9.30 | $1.5M | 13,798,864 | May 29, 2025 |
| May 29, 2025 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -208,696 | $9.33 | $1.9M | 13,590,168 | May 29, 2025 |
| May 1, 2025 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -108,272 | $8.95 | $969k | 14,268,904 | May 5, 2025 |
| May 1, 2025 | VRNA Verona Pharma plc | MOption exercise Ordinary Shares10b5-1 | +200,000 | - | - | 14,468,904 | May 5, 2025 |
| May 1, 2025 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -78,736 | $8.95 | $705k | 14,390,168 | May 5, 2025 |
| May 2, 2025 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -400,000 | $9.09 | $3.6M | 13,990,168 | May 5, 2025 |
| May 1, 2025 | VRNA Verona Pharma plc | MOption exercise Restricted Share Unitsderivative10b5-1 | -200,000 | $0.00 | $0 | 1,000,000 | May 5, 2025 |
| Apr 29, 2025 | VRNA Verona Pharma plc | MOption exercise Ordinary Shares10b5-1 | +229,512 | $0.00 | $0 | 14,467,536 | May 1, 2025 |
| Apr 29, 2025 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -90,360 | $8.98 | $811k | 14,377,176 | May 1, 2025 |
| Aug 7, 2024 | VRNA Verona Pharma plc | AGrant or award Restricted Share Unitsderivative10b5-1 | +1,200,000 | $0.00 | $0 | 1,200,000 | May 1, 2025 |
| Apr 29, 2025 | VRNA Verona Pharma plc | AGrant or award Restricted Share Unitsderivative10b5-1 | +675,000 | $0.00 | $0 | 675,000 | May 1, 2025 |
| Apr 29, 2025 | VRNA Verona Pharma plc | MOption exercise Restricted Share Unitsderivative10b5-1 | -229,512 | $0.00 | $0 | 445,488 | May 1, 2025 |
| Dec 4, 2024 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -67,608 | $5.00 | $338k | 15,007,816 | Dec 6, 2024 |
| Dec 5, 2024 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -640,264 | $5.01 | $3.2M | 14,367,552 | Dec 6, 2024 |
| Dec 6, 2024 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -162,800 | $5.01 | $815k | 14,204,752 | Dec 6, 2024 |
| Nov 27, 2024 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -23,240 | $5.00 | $116k | 15,177,512 | Dec 2, 2024 |
| Nov 29, 2024 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -98,888 | $5.01 | $495k | 15,078,624 | Dec 2, 2024 |
| Dec 2, 2024 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -3,200 | $5.00 | $16k | 15,075,424 | Dec 2, 2024 |
| Nov 25, 2024 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -1,600 | $5.00 | $8,000 | 15,200,752 | Nov 26, 2024 |
| Nov 11, 2024 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -2,400 | $5.00 | $12k | 15,202,352 | Nov 13, 2024 |
| Nov 1, 2024 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -46,888 | $4.38 | $205k | 15,298,896 | Nov 5, 2024 |
| Nov 4, 2024 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -94,144 | $4.39 | $413k | 15,204,752 | Nov 5, 2024 |
| Oct 30, 2024 | VRNA Verona Pharma plc | AGrant or award Ordinary Shares10b5-1 | +800,000 | $0.00 | $0 | 15,391,736 | Nov 1, 2024 |
| Nov 1, 2024 | VRNA Verona Pharma plc | AGrant or award Ordinary Shares10b5-1 | +200,000 | $0.00 | $0 | 15,591,736 | Nov 1, 2024 |
| Nov 1, 2024 | VRNA Verona Pharma plc | FTax withholding Ordinary Shares10b5-1 | -245,952 | $4.24 | $1.0M | 15,345,784 | Nov 1, 2024 |
| Oct 23, 2024 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -16 | $4.38 | $70 | 14,736,536 | Oct 25, 2024 |
| Oct 24, 2024 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -140,000 | $4.38 | $613k | 14,596,536 | Oct 25, 2024 |
| Oct 25, 2024 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -4,800 | $4.38 | $21k | 14,591,736 | Oct 25, 2024 |
| Oct 18, 2024 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -245,784 | $4.38 | $1.1M | 15,004,920 | Oct 22, 2024 |
| Oct 21, 2024 | VRNA Verona Pharma plc | SOpen-market sale Ordinary Shares10b5-1 | -110,456 | $4.38 | $484k | 14,894,464 | Oct 22, 2024 |
50 of 51 rows shown.
Questions about David Zaccardelli
Answered from the filings on this page, as of the latest one.
Is David Zaccardelli buying or selling?
Not in the last 12 months. David Zaccardelli's latest open-market trade on SEC Form 4 was sold $2.7M of VRNA on Aug 1, 2025.
How did David Zaccardelli's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and David Zaccardelli has 0.
Where does David Zaccardelli file Form 4?
David Zaccardelli has filed Form 4 at VRNA (Verona Pharma plc) as President and CEO; SABS (SAB Biotherapeutics, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.